Neoadjuvant pembrolizumab (3 doses) in stage I–III disease yielded a 71% pCR rate and only one melanoma-specific survival event at 3 years post-resection. Experts discuss the SWOG S1512 trial of ...

While researchers gain new insights into the transmission of Buruli ulcer in Australia, public health specialists in Africa are working to engage traditional healers. Sophie Cousins reports.

Researchers at Griffith University have discovered a tentative but plausible link between nose picking and an increased risk ...